Imipramine Pamoate

Nocturnal Enuresis (bedwetting), Bulimia Nervosa, Panic Disorder + 3 more
Treatment
20 Active Studies for Imipramine Pamoate

What is Imipramine Pamoate

ImipramineThe Generic name of this drug
Treatment SummaryImipramine is a tricyclic antidepressant (TCA) used to treat depression. It works by blocking the reuptake of serotonin and norepinephrine, two neurotransmitters that regulate mood. It also blocks certain receptors in the body, which can lead to side effects such as sedation, low blood pressure, and blurred vision. Imipramine is also sometimes prescribed to treat conditions such as chronic pain, panic disorder, ADHD, and PTSD.
Tofranilis the brand name
image of different drug pills on a surface
Imipramine Pamoate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tofranil
Imipramine
1959
103

Effectiveness

How Imipramine Pamoate Affects PatientsImipramine is a type of antidepressant that helps to treat depression by increasing the levels of serotonin and norepinephrine, two chemicals in the brain that can affect mood. It is similar to other drugs such as amitriptyline and doxepin. When taken, imipramine can lead to changes in the brain such as increased production of nerve cells and reduced stress responses. It is believed that these changes, along with its effect on serotonin, are what make it an effective antidepressant. Additionally, it may cause a decrease in certain receptors in the brain that help to regulate adrenaline.
How Imipramine Pamoate works in the bodyImipramine helps treat depression by blocking the removal of two important neurotransmitters, norepinephrine and serotonin, from the spaces between neurons. This allows these two chemicals to stay in the spaces between neurons longer, stimulating the neurons and relieving symptoms of depression.

When to interrupt dosage

The recommended dosage of Imipramine Pamoate is contingent upon the diagnosed condition, such as Bedwetting, Bulimia Nervosa and Depression. The amount of dosage is dependent on the mode of administration (e.g. Tablet, sugar coated or Tablet, sugar coated - Oral), as indicated in the below table.
Condition
Dosage
Administration
Nocturnal Enuresis (bedwetting)
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Bulimia Nervosa
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Panic Disorder
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Neuropathic Pain
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Depression
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Attention Deficit Hyperactivity Disorder
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Warnings

Imipramine Pamoate has two contraindications and should not be concomitantly administered when afflicted with any of the conditions in the table below.Imipramine Pamoate Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Myocardial Infarction
Do Not Combine
There are 20 known major drug interactions with Imipramine Pamoate.
Common Imipramine Pamoate Drug Interactions
Drug Name
Risk Level
Description
Acepromazine
Major
Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Aclidinium
Major
The risk or severity of adverse effects can be increased when Imipramine is combined with Aclidinium.
Alfuzosin
Major
Imipramine may increase the hypotensive activities of Alfuzosin.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Imipramine.
Amoxapine
Major
Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.
Imipramine Pamoate Toxicity & Overdose RiskTaking too much imipramine can cause dryness in the mouth and eyes, increased body temperature, constipation, difficulty urinating, tiredness, agitation, nightmares, confusion, decreased appetite, stomach pain, vomiting, and a strange taste in the mouth. In rare cases, it can lead to low blood cell counts and blood clotting problems. Infants born to mothers taking imipramine may experience heart problems, fussiness, breathing difficulty, muscle spasms, convulsions, and difficulty urinating. Taking it with other drugs that increase serotonin levels can cause serotonin syndrome. The LD50 for rats is 250mg/
image of a doctor in a lab doing drug, clinical research

Imipramine Pamoate Novel Uses: Which Conditions Have a Clinical Trial Featuring Imipramine Pamoate?

779 active clinical trials are currently assessing the potential of Imipramine Pamoate to provide relief from Attention Deficit Hyperactivity Disorder, Bulimia Nervosa and Depression.
Condition
Clinical Trials
Trial Phases
Attention Deficit Hyperactivity Disorder
63 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2
Nocturnal Enuresis (bedwetting)
2 Actively Recruiting
Not Applicable
Depression
306 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Bulimia Nervosa
0 Actively Recruiting
Panic Disorder
14 Actively Recruiting
Not Applicable
Neuropathic Pain
4 Actively Recruiting
Not Applicable, Phase 1, Phase 2

Imipramine Pamoate Reviews: What are patients saying about Imipramine Pamoate?

4.3Patient Review
1/16/2014
Imipramine Pamoate for Depression
Imipramine has been extremely effective for me in treating my psychiatric problems. I've been taking it for most of my life, and the imipramine pamoate formulation seems to really help with side effects like tremor and dry mouth. The old tricyclic antidepressants have a similar effect to the newer SNRIs but are much cheaper, so Imipramine is a great option.
4.3Patient Review
11/19/2013
Imipramine Pamoate for Depression
The side effects of this medication were really terrible and it made my symptoms worse. I was stressed, agitated, and felt strung-out all the time. I took it for off-label use for ADHD and it is by far the worst medication I have ever taken.
2Patient Review
1/6/2011
Imipramine Pamoate for Depression
I took this medication for its side effect of causing sleep.
1Patient Review
7/1/2013
Imipramine Pamoate for Attention Deficit Disorder with Hyperactivity
Imipramine has helped me a lot with my incontinence issues.

Patient Q&A Section about imipramine pamoate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is imipramine pamoate?

"Imipramine belongs to a class of antidepressants known as tricyclics. It treats depression by increasing the levels of certain chemicals in the brain that are necessary for mental balance."

Answered by AI

What is imipramine pamoate used for?

"This drug is given to people who are suffering from depression. It is thought to work by aiding in the regulation of moods, and may also help with sleep and appetite. It may also give the patient more energy to take part in daily activities. The drug imipramine pamoate is classified as a tricyclic antidepressant."

Answered by AI

What is the difference between Imipramine HCl and pamoate?

"Imipramine HCl is FDA approved for adults and adolescents with depression, as well as bedwetting in children. Imipramine pamoate is only approved to treat depression in adults ages 17 and up."

Answered by AI

Is imipramine used for anxiety?

"Imipramine is a drug that is used to treat depression, anxiety, and panic disorder. It belongs to a class of drugs called tricyclic antidepressants. It is often used to treat bedwetting in children, even though it is not clear how it prevents bedwetting."

Answered by AI

Clinical Trials for Imipramine Pamoate

Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR
The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.
Waitlist Available
Has No Placebo
Lincoln Middle School (+12 Sites)Beth Stormshak, PhD
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.
Phase 1
Recruiting
St. Jude Children's Research HospitalAndrew Heitzer, PhD
Have you considered Imipramine Pamoate clinical trials? We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.Go to Trials
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.
Recruiting
Has No Placebo
Mayo Clinic in FloridaJuan C. Cardenas Rosales, MD
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA
The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.
Phase 2
Recruiting
University of California, Los Angeles
Have you considered Imipramine Pamoate clinical trials? We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth College in Lebanon, United States.

Advertising Claims for Anxiety and Depression

18+
All Sexes
Lebanon, NH
In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and/or anxiety. The specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases. Analyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations. This research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.
Waitlist Available
Has No Placebo
Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth CollegeJennifer Emond, PHD
Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)
Recruiting
Device
UCSF Nancy Friend Pritzker Psychiatry Building
Have you considered Imipramine Pamoate clinical trials? We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security